Atherothrombogenicity of lipoprotein(a): The debate

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 2, 1998, Pages 26-33

  Scanu, Angela M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; ELASTASE; FIBRINOGEN; FIBRONECTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; PROTEOGLYCAN;

ARTERY WALL; ATHEROGENESIS; BLOOD LEVEL; CELL INTERACTION; CONFERENCE PAPER; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEREDITY; HUMAN; LEUKOCYTE; MACROPHAGE; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOGENICITY;

ANIMALS; ARTERIES; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; LIPOPROTEIN(A); MUTATION; POLYMORPHISM, GENETIC; PROTEIN BIOSYNTHESIS; RISK FACTORS; THROMBOSIS;

EID: 0032511910     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00733-4     Document Type: Article

References (91)

1. Berg K. A new serum type system in man: Lp system. Acta Pathol Microbiol Scand 1963;59:369-382.
2. Scanu AM. Structural basis for the presumptive atherothrombogenic action of lipoprotein(a). Biochem Pharmacol 1993;46:1675-1680.
3. Scanu AM, Fless GM. Lp(a): lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990;85:1709-1715.
4. Scanu AM, Edelstein C. Learning about the structure and biology of human lipoprotein(a) through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res 1997;38:2193-2206.
5. Lawn RM, Scanu AM. Lipoprotein(a). In: Fuster V, ROSS R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven Publishers, 1996:151-161.
6. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 7th ed., vol 2. New York: McGraw-Hill, 1995:1887-1912.
7. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-137.
8. Makino K, Scanu AM. Lipoprotein(a): non-human primate models. Lipids 1991;26:679-683.
9. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
10. Wade DP. Lipoprotein(a). Curr Opin Lipidol 1993;4:244-249.
11. Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphism in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 1993;91:1630-1636.
12. Mooser V, Mancini FP, Bopp S, Petho-Schramm A, Guerra R, Boerwinkle E, Muller HJ, Hobbs H. Sequence polymorphism in the apo(a) gene associated with specific levels of Lp(a) in the plasma. Hum Mol Genet 1995;4:173-181.
13. Trommnsdorf M, Kochl S, Krononberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Foegerman O, Utermann G, Kraft HG. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995;96:150-157.
14. Kraft HG, Windegger M, Menzel HJ, Utermann G. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet 1998;7:257-264.
15. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995;15:58-64.
16. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the apo(a) gene, apo(a) glycoprotein and plasma concentrations of Lp(a) in three ethnic groups - evidence for no common Lp(a) allele at the apo(a) locus. J Clin Invest 1994;93:2526-2534.
17. Albers JJ, Taggart HMc A, Applebaum-Bowden D, Haffner S, Chestnut CH III, Hazzard WR. Reduction of lecithin-cholesterol acyl transferase, apolipoprotein D and Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 1984;795:293-296.
18. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels: opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992;89:1166-1172.
19. Soma MR, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett JD, Meschia M, Crosignani P. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993;153:1462-1468.
20. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106-1110.
21. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol 1993;13:296-301.
22. Olivecrona H, Ericsson S, Berglund L, Angelin B. Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment. BMJ 1993;306:1726-1727.
23. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-1. Arterioscler Thromb Vasc Biol 1995;15:847-849.
24. DeBruin TWA, Van Barlinhen H, Van Linde-Sibenius Trip M, Van Vurstde-Vries ASR, Akveld NJ, Erkelens DW. Lipoprotein(a) and apoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrinol Metab 1993;76:121-126.
25. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987;33:721-725.
26. Thillet J, Faucher C, Issad B, Allouache M, Chap J, Jacobs C. Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;22:226-232.
27. Goldwasser P, Michel MA, Collier J, Mittman N, Fein PA, Gusik S-A, Avram M. Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis 1993;22:215-225.
28. Buggy D, Breathnach A, Keogh B, Cooke T, Feely J. Lipoprotein(a) and treatment of chronic renal disease. J Intern Med 1993;234:453-455.
29. Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara S, Naito S, Kajiyama G, Arakawa K. Serum lipoprotein(a) levels in maintenance hemodialysis patients. Nephron 1993;65:46-50.
30. Haffner SM, Gruber KK, Aldrete GJ, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol 1992;3:1156-1162.
31. Dieplinger H, Lackner C, Kronenberg F, Sanholzer C, Lhotta K, Hopplicher F, Graf H, Konig P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993;91:397-401.
32. Barbagallo CM, Averna MR, Sparacino V, Galione A, Caputo F, Scafidi V, Amato S, Mancino C, Cefalu AB, Notarbartolo A. Lipoprotein(a) levels in end-stage renal failure and renal transplantation. Nephron 1993;64:560-564.
33. Black IW, Wilken DE. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992;38:353-357.
34. Kanno H, Saito E, Fujioka T, Yasugi T. Lipoprotein(a) levels in the nephrotic syndrome. Intern Med 1992;31:1004-1008.
35. Short CD, Durrington PN, Mallick NP, Bhatnagar D, Hunt LP, MBewu A. Serum lipoprotein(a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant 1992;7:109-113.
36. Karadi I, Romics L, Palos G, Doman J, Kaszas I, Hesz A, Kostner GM. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989;35:2121-2123.
37. Lenzi S, Scanu AM, De Caterina R. Lipoprotein(a) as an athero-thrombotic genetic risk factor: epidemiological evidence and possible pathogenetic mechanisms. G Ital Cardiol 1996;26:1203-1225.
38. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989;78:145-150.
39. Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, Shimokawa K. Lp(a): an acute-phase reactant? Chem Phys Lipids 1994;67-68:411-417.
40. Bewu M, Durrington PR, Bulleid S, Mackness MI. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoprotein Al and B, lipids and C-reactive protein. Atherosclerosis 1993;103:67-71.
41. Borba EF, Santos RD, Bonfa E, Vinagre P, Cossermelli W, Maranhow R. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994;21:220-223.
42. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen GH. Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:366-370.
43. Wang J, Mimuro S, Lahoud R, Trudinger B, Wang XL. Elevated levels of lipoprotein(a) in women with preeclampsia. Am J Obstet Gynecol 1998;178:146-149.
44. 1 are altered in pre-eclampsia. Clin Genet 1997;52:371-376.
45. Lippi G, Braga V, Adami S, Guidi G. Modification of serum apolipoprotein A-1, apolipoprotein B and lipoprotein(a) levels after biphosphonate-induced acute phase response. Clin Chim Acta 1998;271:79-87.
46. Wu T, Padmanabhan A, Tulinsky A, Mulichak AM. The refined structure of the ε-aminocaproic acid complex of human plasminogen kringle 4. Biochemistry 1991;30:10589-10594.
47. 37. J Clin Invest 1993;91:283-291.
48. Scanu AM, Pfaffinger D, Lee JC, Hinman J. A single point mutation (Trp72-Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994;1227:41-45.
49. Klezovitch O, Scanu AM. Lysine and fibrinogen binding of wild type (Trp72) and mutant (Arg72) human apolipoprotein(a) kringle IV-10 expressed in E. coli and CHO cells. Arterioscler Thromb Vasc Biol 1996;16:392-398.
50. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants in lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995;34:16483-16492.
51. Ernst A, Helmhold M, Brunner C, Pethoschramm A, Armstrong VW, Muller HJ. Identification of two functionally distinct lysine binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995;270:6227-6234.
52. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res 1996;37:1786-1801.
53. Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. J Biol Chem 1997;272:11079-11087.
54. Scanu AM, Atzeni MM, Edelstein C, Tonolo G, Maioli M, Klezovitch O. Lipoprotein(a): identification of subjects with a superbinding capacity for fibrinogen. Clin Genet 1997;52:367-370.
55. Prins J, Leus FR, van der Hoek YY, Kastelein JJP, Bouma BN, van Rijn HJM. The identification and significance of a Thr-→Pro polymorphism in kringle IV type 8 of apolipoprotein(a). Thromb Haemost 1997;77:949-954.
56. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;267:4143-4151.
57. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of Lp(a) and the effect of beta carotene. Metabolism 1992;41:1215-1224.
58. de Rijke YB, Jurgens G, Hessels EMAJ, Hermann A, van Berkel TJC. In vivo fate and scavenger receptor recognition of oxidized lipoprotein(a) isoforms in rats. J Lipid Res 1992;33:1315-1325.
59. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Metalloproteinase-2 cleaves lipoprotein(a) and apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. (Abstr.) Circulation 1997;96(suppl):111.
60. Mooser V, Sabra MC, Abedin M, Landschultz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in human urine: relationship to plasma levels of lipoprotein(a). J Clin Invest 1996;97:858-864.
61. 2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low density lipoprotein. Arterioscler Thromb Vasc Biol 1996;17:300-309.
62. 2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998;79:640-648.
63. Xu X, Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesterol ester accumulation in macrophages. J Biol Chem 1991;266:24849-24858.
64. Wild SH, Fortmann SP, Marcovina S. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol 1997;17:239-245.
65. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglescano E. Does apolipoprotein heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993;82:392-397.
66. Leerink CB, Duif PFCCM, Gimpel JA, Kortlandt W, Bouma BN, van Rijn HJM. Lysine binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost 1992;68:185-188.
67. Hopkins PN, Lily L, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997;17:2783-2792.
68. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien BJ, Dajenais RG. Lipoprotein(a) an independent risk factor for ischemic heart disease in man? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-525.
69. Rath M, Niendorf A, Reblin T, Krebber HJ, Beisigel U. Detection and quantification of lipoprotein(a) in the arterial wall of coronary bypass surgery. Arteriosclerosis 1989;9:579-592.
70. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991;32:317-327.
71. Polacek D, Byrne RE, Scanu AM. Modifications of low density lipoproteins by polymorphonuclear cell elastase lead to enhanced uptake by human monocyte derived macrophages via the low-density receptor pathway. J Lipid Res 1988;29:797-808.
72. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase atherogenicity. N Engl J Med 1989;320:915-924.
73. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost 1990;63:331-335.
74. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a): fibrin binding and plasminogen activation. Arteriosclerosis 1990;10:240-245.
75. Grainger DI, Kirschenlor HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655-1658.
76. Salonen EM, Jauhianen M, Zardi L, Vaheri A, Enholm C. Lipoprotein(a) binds to fibronectin and has serine protease activity capable of cleaving it. EMBO J 1989;8:4035-4040.
77. Klezovitch O, Edelstein C, Scanu AM. Apolipoprotein(a) binds to proteoglycan decorin via its C-terminal domain. J Biol Chem 1998;273:23856-23865.
78. Poon M, Zhang X, Dunsky K, Taubman MB, Harpel PC. Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet 1997;52:308-313.
79. Takami S, Yamashita S, Kihara S, Ishigami M, Takemura K, Kume N, Kita T, Matsuzawa Y. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998;97:721-728.
80. Brown BG, Maher V. Lipoprotein(a) and coronary heart disease. Current Opin Lipidol 1995;6:229-235.
81. Dahlen GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease, pathogenetic mechanisms and clinical significance. Clin Genet 1997;52:272-280.
82. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and thrombosis. Circulation 1997;96:4095-4101.
83. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1991;1081:65-74.
84. Angelin B. Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol 1997;8:337-341.
85. Morgan JM, Capuzzi DM, Guyton JR, Center RM, Goldberg R, Robbins DC, DiPette D, Jenkins S, Marcovina S. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
86. Edelstein C, Davidson NO, Scanu AM. Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes. Chem Phys Lipids 1994;67/68:135-143.
87. Treasure CB, Klein JL, Weintraub WS, Talley DJ, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
88. Lawn R, Liu A, Verstuift J, Rubin E. Human apolipoprotein A-1 prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice. J Lipid Res 1994;35:2263-2267.
89. Welch GN, Loscalzo J. Mechanics of disease: homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
90. Husain S, Andrew NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-720.
91. Kreuzer J, Lloyd MB, Bok D, Fless GM, Scanu AM, Lusis AJ, Haberland ME. Lipoprotein(a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall. Chem Phys Lipids 1994;67/68:175-190.